Jefferies raised the firm’s price target on Denali Therapeutics (DNLI) to $45 from $40 and keeps a Buy rating on the shares ...

Denali Therapeutics Inc (NASDAQ:DNLI) shares are moving lower in Thursday’s after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. What Happened ...

In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) stands against the other stocks Jeff Bezos is buying. Jeff Bezos is a name closely tied to Amazon the ...

On Friday, Denali Therapeutics Inc (DNLI) stock saw a modest uptick, ending the day at $27.05 which represents a slight increase of $1.09 or 4.20% from the prior close of $25.96. The stock opened at ...

Oct 10 (Reuters) - Denali Therapeutics (DNLI.O), opens new tab said on Thursday its partner Sanofi (SASY.PA), opens new tab has discontinued a mid-stage study testing their experimental drug to ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a ...

On Monday, Denali Therapeutics Inc (DNLI) stock saw a modest uptick, ending the day at $27.78 which represents a slight increase of $1.63 or 6.23% from the prior close of $26.15. The stock opened at ...

Biogen (NASDAQ: BIIB) reported second-quarter 2024 adjusted earnings per share of $5.28, beating the Zacks Consensus Estimate of $4.00. Earnings rose 31% year over year. Earnings benefited from ...

Denali Therapeutics announces its Phase 2 study of oditrasertib was discontinued. Denali's strategic partner says the study failed to meet the primary and key secondary endpoints. Denali ...

Jefferies raised the firm’s price target on Denali Therapeutics (DNLI) to $45 from $40 and keeps a Buy rating on the shares ahead of the company reporting first DNL-126 Phase 1/2 data in ...